Therapeutic Operations Lead.
Orchard Therapeutics is a fully integrated company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies.
Orchard's portfolio of cutting-edge ex vivo autologous gene therapy programs has demonstrated sustained clinical benefit in over 150 patients across five disease areas. The pipeline includes Strimvelis, the first EMA approved ex vivo gene therapy for adenosine deaminase severe combined immunodeficiency or ADA-SCID and six clinical-stage programmes targeting neurometabolic disorders, primary immune deficiencies and blood disorders. The company has submitted an application for market authorization with EMA for LIBMELDY (OTL-200) targeting metachromatic leukodystrophy or MLD in November 2019, and an approval is anticipated by the end of 2020. Further submissions for a BLA and an MAA are planned in 2021 for its programme in Wiskott-Aldrich Syndrome (OTL-103).
In anticipation of the launch of its therapies in France, Orchard is looking to appoint a Therapeutic Operations Lead , to lead the commercialization of Orchard's transformative gene therapies in neurometabolic disorders. Reporting to the General Manager Orchard France & Benelux, the Therapeutic Operations Lead will be responsible for delivering the company's commercial business in neurometabolic disorders. This will include building trusted relationships with qualified treatment centers, healthcare professionals and patient organizations and leading the commercialisation of LIBMELDY in France.
This is a unique opportunity to contribute to the rapid growth and success of a leading biotechnology company with a transformative technology.
Key elements and responsibilities:
Develop trusted relationships with qualified treatment centers, healthcare professionals and patient organizations In collaboration with the global quality and distribution teams, facilitate site qualification activities and resolve issues arising...